150 related articles for article (PubMed ID: 9574706)
1. Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to amoxicillin-clavulanate (Augmentin).
Simpson I; Durodie J; Knott S; Shea B; Wilson J; Machka K
J Clin Microbiol; 1998 May; 36(5):1361-5. PubMed ID: 9574706
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians?
Patry I; Hocquet D; Talon D; Plesiat P; Bertrand X
Clin Microbiol Infect; 2005 Mar; 11(3):237-40. PubMed ID: 15715724
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.
Doern GV; Brueggemann AB; Pierce G; Holley HP; Rauch A
Antimicrob Agents Chemother; 1997 Feb; 41(2):292-7. PubMed ID: 9021182
[TBL] [Abstract][Full Text] [Related]
4. Effect of NCCLS, SFM, and DIN breakpoints upon the incidence of co-amoxiclav resistance in Escherichia coli.
Durodia J; Simpson I
J Antimicrob Chemother; 1995 Dec; 36(6):1105-6. PubMed ID: 8821615
[No Abstract] [Full Text] [Related]
5. Cefotaxime and Amoxicillin-Clavulanate Synergism against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Urinary Tract Infection.
Rossi B; Soubirou JF; Chau F; Massias L; Dion S; Lepeule R; Fantin B; Lefort A
Antimicrob Agents Chemother; 2016 Jan; 60(1):424-30. PubMed ID: 26525800
[TBL] [Abstract][Full Text] [Related]
6. Study of the in vitro activity of amoxicillin/clavulanic acid and other beta-lactam antibiotics against Escherichia coli isolated from urine specimens.
Vanhoof R; Carpentier M; Delannoy P; Fagnart O; Lontie M; Mans I; Nyssen HJ; Van Nimmen L
Acta Clin Belg; 2001; 56(1):32-7. PubMed ID: 11307481
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
8. [Resistance of Escherichia coli isolated from the urinary tract to amoxicillin-clavulanic acid and other antibiotics].
Ferjani A; Marzouk M; Ben Moussa F; Boukadida J
Med Mal Infect; 2010 Mar; 40(3):161-4. PubMed ID: 19616395
[TBL] [Abstract][Full Text] [Related]
9. A combination of mecillinam and amoxicillin/clavulanate can restore susceptibility of high-level TEM-1-producing Escherichia coli to mecillinam.
Birgy A; Delecourt M; Geslain G; Desselas E; Caseris M; Magnan M; Mariani-Kurkdjian P; Bidet P; Bonacorsi S
J Antimicrob Chemother; 2017 Jul; 72(7):1911-1914. PubMed ID: 28369441
[TBL] [Abstract][Full Text] [Related]
10. Amoxicillin and amoxicillin-clavulanate resistance in urinary Escherichia coli antibiograms of cats and dogs from the Midwestern United States.
KuKanich K; Lubbers B; Salgado B
J Vet Intern Med; 2020 Jan; 34(1):227-231. PubMed ID: 31777977
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of amoxycillin-clavulanate in an experimental model of murine pneumonia caused by AmpC-non-hyperproducing clinical isolates of Escherichia coli resistant to cefoxitin.
Docobo-Pérez F; Fernández-Cuenca F; Pachón-Ibáñez ME; Pascual A; Pichardo C; Martínez-Martínez L; Pachón J
Clin Microbiol Infect; 2008 Jun; 14(6):582-7. PubMed ID: 18294246
[TBL] [Abstract][Full Text] [Related]
12. Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes.
Díez-Aguilar M; Morosini MI; López-Cerero L; Pascual Á; Calvo J; Martínez-Martínez L; Marco F; Vila J; Ortega A; Oteo J; Cantón R
J Antimicrob Chemother; 2015 Aug; 70(8):2306-10. PubMed ID: 25900161
[TBL] [Abstract][Full Text] [Related]
13. Establishing the validity of different susceptibility testing methods to evaluate the in vitro activity of amoxicillin-clavulanate against Escherichia coli.
María DA; María-Isabel M; María-Carmen C; Álvaro P; Jorge C; Luis MM; Francesc M; Jordi V; Adriana O; Jesús O; Rafael C
Diagn Microbiol Infect Dis; 2016 Apr; 84(4):334-6. PubMed ID: 26830054
[TBL] [Abstract][Full Text] [Related]
14. [Ampicillin-sulbactam activity against respiratory isolates of Haemophilus influenzae].
Cisterna R; Fresnadillo MJ; García-Rodríguez JA; Gobernado M; Martín R; Perea E; Picazo J
Rev Esp Quimioter; 1998 Sep; 11(3):245-50. PubMed ID: 9795311
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey.
Pierard D; De Meyer A; Rosseel P; Van Cauwenbergh M; Struelens MJ; Delmee M; Goossens H; Claeys G; Glupczynski Y; Verbist L; Melin P; Lauwers S
Acta Clin Belg; 1996; 51(2):70-9. PubMed ID: 8693871
[TBL] [Abstract][Full Text] [Related]
16. Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/clavulanic acid: a phase I, open-label, noncomparative clinical trial in healthy volunteers.
Ponte C; Gracia M; Giménez MJ; Aguilar L; Maín CM; Carpintero Y; Huelves L; Carcas A; del Prado G; Soriano F
Clin Ther; 2005 Jul; 27(7):1043-9. PubMed ID: 16154483
[TBL] [Abstract][Full Text] [Related]
17. A comparison of E. coli susceptibility for amoxicillin/clavulanic acid according to EUCAST and CLSI guidelines.
Vanstokstraeten R; Belasri N; Demuyser T; Crombé F; Barbé K; Piérard D
Eur J Clin Microbiol Infect Dis; 2021 Nov; 40(11):2371-2377. PubMed ID: 34175999
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
Pottumarthy S; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
Kassim A; Omuse G; Premji Z; Revathi G
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():21. PubMed ID: 27068515
[TBL] [Abstract][Full Text] [Related]
20. MIC of amoxicillin/clavulanate according to CLSI and EUCAST: discrepancies and clinical impact in patients with bloodstream infections due to Enterobacteriaceae.
Delgado-Valverde M; Valiente-Mendez A; Torres E; Almirante B; Gómez-Zorrilla S; Borrell N; Aller-García AI; Gurgui M; Almela M; Sanz M; Bou G; Martínez-Martínez L; Cantón R; Antonio Lepe J; Causse M; Gutiérrez-Gutiérrez B; Pascual Á; Rodríguez-Baño J;
J Antimicrob Chemother; 2017 May; 72(5):1478-1487. PubMed ID: 28093484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
